TIME TO MARKET AND PRICE COMPARISON FOR BIOSIMILAR DRUGS IN EU5

被引：0
|
作者：
Lopez, N. [1 ]
Prada, M. [2 ]
Berard, I [3 ]
Schleich, W. [4 ]
Melson, C. [5 ]
机构：
[1] Oblikue Consulting SL, Barcelona, Spain
[2] Intexo, Rome, Italy
[3] NEXTEP, Paris, France
[4] MArS Market Access & Pricing Strategy GmbH, Ansbach, Germany
[5] Decideum Ltd, London, England
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.09.1111
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PHP217
引用
收藏
页码：S186 / S187
页数：3
相关论文
共 50 条
  • [1] A PRICE COMPARISON STUDY OF RECENT DRUGS IN EU5, 2008-2012
    Le Pen, C.
    Vigier, D.
    Grandfils, N.
    VALUE IN HEALTH, 2013, 16 (07) : A455 - A455
  • [2] TIME FOR REIMBURSEMENT FOR ORPHAN DRUGS IN EU5
    Prada, M.
    Berard, I
    Walzer, S.
    Darba, J.
    Greenwood, B.
    VALUE IN HEALTH, 2018, 21 : S264 - S264
  • [3] TIME TO REIMBURSEMENT FOR ONCOLOGY DRUGS IN EU5
    Prada, M.
    Berard, I
    Walzer, S.
    Darba, J.
    Greenwood, B.
    VALUE IN HEALTH, 2018, 21 : S47 - S47
  • [4] FUTURE TRENDS ON THE BIOSIMILAR UPTAKE IN THE EU5 AND THE US
    Lach, S.
    Sroka, A.
    Remuzat, C.
    Toumi, M.
    VALUE IN HEALTH, 2019, 22 : S427 - S427
  • [5] PRICE-DOSE RELATIONSHIP: THE CASE OF ORAL ONCOLOGY DRUGS IN EU5
    Czira, A.
    Pacheco, L.
    Teale, C. W.
    VALUE IN HEALTH, 2017, 20 (09) : A430 - A430
  • [6] AN ANALYSIS OF PRICE AND ACCESS TIMELINE OF ONCOLOGY DRUGS ACROSS EU5 COUNTRIES
    Wang, X.
    VALUE IN HEALTH, 2018, 21 : S22 - S22
  • [7] TIME TO REIMBURSEMENT FOR ORPHAN DRUGS IN EU5 IN THE LAST FIVE YEARS
    Molchanova, E.
    Benazet, F.
    Vollmer, L.
    Pomares, E.
    Danev, V
    Prada, M.
    VALUE IN HEALTH, 2020, 23 : S701 - S701
  • [8] TIME FOR REIMBURSEMENT FOR ORPHAN DRUGS IN EU5 IN THE LAST THREE YEARS
    Prada, M.
    Benazet, F.
    Berard, I
    Vollmer, L.
    Cuesta, M.
    Guterres, S.
    VALUE IN HEALTH, 2019, 22 : S854 - S854
  • [9] PERCEPTIONS OF BIOSIMILAR MONOCLONAL ANTIBODIES AMONGST EU5 BUDGET HOLDERS
    Gardiner, R. B.
    VALUE IN HEALTH, 2015, 18 (03) : A200 - A201
  • [10] ORIGINAL VS BIOSIMILAR DRUGS PRICE DIFFERENCES IN EU COUNTRIES
    Psenkova, M.
    Mackovicova, S.
    VALUE IN HEALTH, 2019, 22 : S680 - S680
12345